drugset / Trial / NCT04809181
Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
Phase 2
Unknown
95 enrolled
First Affiliated Hospital of Zhejiang University
First Affiliated Hospital of Wenzhou Medical University · collabJinhua Central Hospital · collabNingbo No. 1 Hospital · collabSecond Affiliated Hospital, School of Medicine, Zhejiang University · collabSir Run Run Shaw Hospital · collabTaizhou Hospital · collabThe First Affiliated Hospital of Zhejiang Chinese Medical University · collabUnion hospital of Fujian Medical University · collabXiangya Hospital of Central South University · collabYinzhou Hospital Affiliated to Medical School of Ningbo University · collabZhejiang Provincial People's Hospital · collab
NaSingle-groupOpen-labelPrevention
Summary
In patients with MRD-positive patients after AML/MDS allogeneic hematopoietic stem cell transplantation, azacytidine combined with venetoclax may be effective in eliminating micro residual diseases, reducing the risk of relapse, and ultimately improving long-term survival.The primary purpose of this study was to explore an effective protocol to reduce the risk of relapse in patients with MRD positive after allogeneic hematopoietic stem cell transplantation for AML/MDS.
Timeline
- Start
- 2021-03-19
- Primary completion
- 2024-03-19
- Completion
- 2026-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | Venetoclax | Small molecule | — | — |